Biosimilar Newsletter Archive

  1. 03.26.20 -- 3 Biosimilar Questions Facing FDA, FTC, & Manufacturers 3/26/2020
    03/26/20 Biosimilar Development Newsletter
  2. 03.25.20 -- Modernizing Cell Therapy Manufacturing 3/25/2020
    03/25/20 Biosimilar Development Newsletter
  3. 03.19.20 -- How Can Hospitals Lead The Biosimilar Charge? 3/19/2020
    03/19/20 Biosimilar Development Newsletter
  4. 03.18.20 -- Uncover The Next Generation Of Immunotherapies 3/18/2020
    03/18/20 Biosimilar Development Newsletter
  5. 03.12.20 -- What Could Transform Biologics Reimbursement? 3/12/2020
    03/12/20 Biosimilar Development Newsletter
  6. 03.11.20 -- 3 Questions To Map Your Future In Biomanufacturing 3/11/2020
    03/11/20 Biosimilar Development Newsletter
  7. 03.05.20 -- Encouraging Biosimilar Use With The "WWKD?" Approach 3/5/2020
    03/05/20 Biosimilar Development Newsletter
  8. 02.27.20 -- How Kaiser Permanente Built A Biosimilar Empire 2/27/2020
    02/27/20 Biosimilar Development Newsletter
  9. 02.26.20 -- Do You Have The Right Tools To Determine CQA? 2/26/2020
    02/26/20 Biosimilar Development Newsletter
  10. 02.20.20 -- The Nurse's Perspective On Biosimilars 2/20/2020
    02/20/20 Biosimilar Development Newsletter